Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Dermatologic 2Lymphoid 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interleukin-12 Subunit p35 × Dermatologic × Clear all
NCT00002952 2013-09-05

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

University of Chicago

Phase 1/2 Completed
20 enrolled
Dermatologic

Melanoma

NCT00052377 2013-01-16

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

National Cancer Institute (NCI)

Phase 1/2 Terminated
46 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡